NEWARK, Del, March 20, 2023 (GLOBE NEWSWIRE) -- The global AL amyloidosis therapeutics market is expected to be worth US$ 2.25 billion by the year of 2023. The market, which is estimated to be worth US$ 4.56 billion by 2033, will grow at a 7.3% CAGR, according to the market intelligence firm, Future Market Insights.
AL amyloidosis is an uncommon illness characterized by aberrant protein buildup in organs and tissues. It frequently results in bodily tissue disintegration or damage, which can seriously harm organs. Weight loss, weakness, exhaustion, dyspnea (inability to breathe deeply when exerting oneself), and joint pain are all symptoms. As a result of excessive water retention, the skin may appear red and have spider veins on the chest and arms. The ageing population, growing incidence rates, and increased prevalence of AL amyloidosis are the main factors propelling the growth of the worldwide AL amyloidosis therapeutics market. One of the main factors accelerating this market's expansion is the expansion of the supply of innovative therapeutic medications.
According to data from the American Society of Clinical Oncology, around 4000 Americans are diagnosed with AL amyloidosis each year, with most cases occurring in persons between the ages of 50 and 65. Just a few persons in their late 20s have received an AL amyloidosis diagnosis. Consequently, the market for AL amyloidosis treatments will expand along with an increase in the senior population.
For More Insights on this Market, Get A Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16805
The governments of several nations are funding the development of medicines and other AL amyloidosis treatment options. Several developed countries also have technologically improved diagnostics and advanced medical therapies. Hence, the market in such areas will prosper with more assistance from the government or other approving agencies.
Chemotherapy is the most important treatment segment in this market, with a fast expanding CAGR value. This is due to the fact that many patients choose it as one of the most successful kinds of treatment. Chemotherapy is often given orally as a medication or through an intravenous line. The growth rate of targeted therapy will accelerate in the upcoming years. Anti-angiogenesis treatment, monoclonal antibodies, as well as proteasome inhibitors are examples of targeted therapeutics. Such factors are expected to bring in new opportunities in the global AL amyloidosis therapeutics market during the forecast period.
Key Takeaways from the Market Study
- The market for treatments for AL amyloidosis expanded at a CAGR of 5.1% from 2018 to 2022.
- More than US$ 2.1 billion is presently spent on treating AL amyloidosis worldwide.
- Chemotherapy is predicted to command the market in 2023 with a 53% revenue share.
- The hospital pharmacy sector by distribution channel will hold the second-largest segment during the anticipated period, with a 25% worldwide market share in 2023.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 7.9%.
- From 2023 to 2033, the Asia Pacific AL amyloidosis therapies market is anticipated to expand at a stable CAGR of 7.6%.
“Due to factors including rising incidence as well as the anticipated introduction of innovative therapeutics throughout the projected period, the market for AL amyloidosis therapeutics is predicted to rise favorably.” comments a Future Market Insights analyst.
Want your report customized? Speak to an analyst and personalize your report according to your needs@ https://www.futuremarketinsights.com/ask-question/rep-gb-16805
Competitive Landscape
Some of the top players in the global intraocular lymphoma disease market are:
- Janssen Pharmaceutical
- Prothena
- Alexion Pharmaceuticals
- Oncopeptides AB
- Bristol-Myers Squibb
- GlaxoSmithKline Pharmaceuticals Ltd
- Celgene Corp
- Eidos Therapeutics, Inc.
- Corino Therapeutics, Inc.
- Spectrum Pharmaceuticals, Inc.
- Pfizer
Some of the recent developments in this domain are:
- The U.S. Food and Drug Administration (FDA) approved Sorrento Therapeutics, Inc.'s experimental new drug application for STI-6129, a CD38-targeting monoclonal antibody combination, in 2020. Sorrento Therapeutics is currently working on a number of technological platforms, along with a CD38-specific antibody found in its completely human G-MABTM antibody library, its own pharmacological payload Duostatin 5, as well as its site-specific C-LOCK coupling technology. These platforms are all used by STI-6129.
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global intraocular lymphoma treatment market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.
To understand opportunities in the intraocular lymphoma treatment, the market is segmented on the basis of treatment (chemotherapy, supportive care, surgery, stem cell transplant, targeted therapy), drugs (transthyretin transport inhibitor, immunomodulatory drugs, monoclonal antibodies, proteasome inhibitors, others), distribution channel (hospital pharmacies, retail pharmacies and online pharmacies) and across major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).
To Gain More Insights about this Research, Visit@ https://www.futuremarketinsights.com/reports/al-amyloidosis-therapeutics-market
Key Segments Covered in the AL amyloidosis therapeutics market Report
By Treatment:
- Chemotherapy
- Supportive Care
- Surgery
- Stem Cell Transplant
- Targeted Therapy
By Drugs:
- Transthyretin Transport Inhibitor
- Immunomodulatory Drugs
- Monoclonal Antibodies
- Proteasome Inhibitors
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Table of Content
1. Executive Summary | AL Amyloidosis Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
Buy Now@ https://www.futuremarketinsights.com/checkout/16805
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analysing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
Have a Look at Related Reports of Healthcare domain
Steroid-Free Nasal Sprays Market Size: The global steroid-free nasal sprays market was valued at US$ 7.7 Billion in 2021 and is expected to reach US$ 14.9 Billion by 2032, with sales growing at a 6.3% CAGR over the assessment period.
Melatonin Sleep Supplements Market Share: The melatonin sleep supplements market is likely to grow its revenue to US$ 474 Million in 2022 and is anticipated to cross US$ 1,059 Million by 2032.
Spinal Osteosynthesis Units Market Demand: Spinal Osteosynthesis Units market is expected to grow at a steady CAGR of 4.8% between 2022 and 2032, surpassing US$ 3.9 Billion by 2032.
Prophylactic HIV Drugs Market Forecast: Demand for prophylactic HIV drugs is projected to register 4%CAGR between 2022 and 2032, totaling over US$ 40 Billion in 2028.
Antimicrobial Coated Medical Devices Market Trends: Global antimicrobial coated medical devices market is anticipated to be valued at US$ 1,344 Million in 2022, forecast to grow at a CAGR of 13.1% to be valued at US$ 5,205.2 Million from 2022 to 2032.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centers in the UK, US, and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-845-579-5705
LinkedIn| Twitter| Blogs | YouTube
For Sales Enquiries: sales@futuremarketinsights.com
